Alicia Morgans is an Oncology physician affiliated with Dana-Farber Cancer Institute. OpenAlex indexes 488 publications with 11,058 citations (h-index 43); ClinicalTrials.gov lists 5 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
450 Brookline Ave
Boston, MA 022155450
Telephone
617-632-6534Provider last certified this registry record 26 Jul 2023.
Clinical trials
- A Study of Talazoparib With or Without Enzalutamide in People With Prostate Cancer Who Have Previously Received Abiraterone Acetate or Darolutamide
Sponsor: Prostate Cancer Clinical Trials Consortium
- CV CARE: CardioVascular Care in PC Patients
Sponsor: Dana-Farber Cancer Institute
- RecoverPC: Relugolix vs GnRH Agonist in Quality of Life
Sponsor: Dana-Farber Cancer Institute
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
31 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- PFIZER INC.Program year202510 payments$34,078openpaymentsdata.cms.gov ↗
- AstraZeneca Pharmaceuticals LPProgram year20256 payments$14,964openpaymentsdata.cms.gov ↗
- Sumitomo Pharma America, Inc.Program year20253 payments$11,973openpaymentsdata.cms.gov ↗
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
58.5%Gonadotropin Releasing Hormone Receptor Antagonist20.6%Orgovyx100%Part D≥14 patientsAnti-androgens14.6%Nubeqa100%Part D<11 patients+ 2 more classes in this area
Metabolism & gastrointestinal
29.5%Corticosteroid29.5%Prednisone100%Part D≥22 patientsGenitourinary & hormones
12.1%alpha-Adrenergic Blocker7%Tamsulosin Hcl100%Part D<11 patientsCholinergic Muscarinic Antagonist5.1%Oxybutynin Chloride Er100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Management of Prostate Cancer in Older Adults
American Society of Clinical Oncology Educational Book
2023
Similar KOLs
Other experts from the same institution or the same specialty.
Kenneth Anderson, MD
Dana-Farber Cancer Institute
Paul Richardson, MD
Dana-Farber Cancer Institute
Toni Choueiri, MD
Dana-Farber Cancer Institute
Pasi Janne, MD, PhD
Dana-Farber Cancer Institute
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”